Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's ...
The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the risk of serious kidney injury that can result from dehydration. This comes ...
AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across various therapeutic areas, including diabetes.
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...
On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...
The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide (Byetta, ...
Treatments for Dupuytren’s contracture include limited fasciectomy and collagenase injection. Comparisons of the effectiveness of these treatments have been limited. We performed an unblinded, ...
INDIANAPOLIS — Eli Lilly is releasing single-dose vials of weight loss drug Zepbound that will help adults living with obesity. Zepbound 2.5 mg and 5 mg single-dose vials are available for patients ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback